ProQR Therapeutics N.V
NASDAQ:PRQR
| Market Cap (Intraday) | 509.26M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $7.82 |
| 50-Day MA | $7.19 |
| 200-Day MA | $6.13 |
ProQR Therapeutics N.V Stock, NASDAQ:PRQR
Zernikedreef 9, Leiden, Zuid-Holland 2333 CK
Phone: +31.88.166.70.00
Number of Employees: 150.4
Description
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Its product pipeline include Sepofarsen, QR-421a, QR-1123, and QR-504a. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer, and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.